对于具有同时存在的Duffy-Null现象型的Graves疾病的管理
Grace M Ferri1, Cassandra Chua1, Alexa R Trovato1
1Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA 02118, USA.
JCEM case reports
|July 29, 2025
概括
临床医生应在开始服用抗甲状腺药物 (ATD) 之前检查白细胞计数,因为可能出现中性衰竭. 患有Duffy-null表型的患者可以安全地接受ATD,尽管中性粒细胞数量较低.
科学领域:
- 内分泌学 在内分泌学.
- 血液学 血液学 血液学
- 遗传学 遗传学 是一个
背景情况:
- 抗甲状腺药物 (ATD) 是格雷夫斯病的主要治疗方法.
- 中性是ATD的潜在副作用,需要进行基线监测.
- 达菲-零血型表型与较低的基线绝对中性粒细胞计数 (ANC) 相关.
研究的目的:
- 在开始ATD之前,强调基线白细胞分数的重要性.
- 报告一个患有Duffy-null表型和基线中性质衰竭的Graves病病例.
- 要强调,在患有Duffy-null表型的患者中不应拒绝ATD.
主要方法:
- 一个37岁的男性患有格雷夫斯病的病例报告.
- 检查患者的中性粒细胞数量和红细胞抗原的类型.
- 给定标准的基于体重的甲基马剂量.
主要成果:
- 患者在诊断时出现了白血病和中性病.
- 红细胞抗原类型检测揭示了达菲-零表型.
- 患者可以耐受甲基马治疗,没有并发症或增加感染风险.
结论:
- 基线中性质减退可能存在于ATD启动之前,并不总是对治疗有禁忌.
- 达菲-零表型与较低的绝对中性粒细胞数量有关,但没有增加感染风险.
- ATD可以安全地给达菲-零表型患者使用,尽管他们的基线中性质减退.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Renal Failure: Dose Adjustments
161
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
161
Adrenal Gland Disorders
1.9K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.9K
Drugs for Treatment of Diarrhea-Predominant IBS
299
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
299
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Synthesis and Regulation of Thyroid Hormones
5.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
5.1K


